API | gft505

gft505 Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Now

Chemistry

SMILES: CSc1ccc(C(=O)/C=C/c2cc(C)c(OC(C)(C)C(=O)O)c(C)c2)cc1
InChIKey: AFLFKFHDSCQHOL-IZZDOVSWSA-N
Mol. Mass: 384.5
ALogP: 5.16 Partition coefficient
ChEMBL Molecule:
elafibranor

More Chemistry

Pharmacology

Mechanisms of Action:
- Peroxisome proliferator-activated receptor alpha (Mesocricetus auratus) ^UniProt
- Peroxisome proliferator-activated receptor alpha (Homo sapiens) ^UniProt
- Peroxisome proliferator-activated receptor delta (Homo sapiens) ^UniProt
- Peroxisome proliferator-activated receptor delta (Homo sapiens) ^UniProt
- Peroxisome proliferator-activated receptor gamma (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid | elafibranor | gft505 | gft-505

Organizations (18)

Research & Development (18)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (19)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (19)

Cardiovascular Diseases (Phase 1)

Cholangitis (Phase 3)

Cholangitis, Sclerosing (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Drug Interactions (Phase 1)

Dyslipidemias (Phase 2)

Geriatrics (Phase 1)

Glucose Intolerance (Phase 2)

Healthy Volunteers (Phase 1)

Insulin Resistance (Phase 2)

Kidney Diseases (Phase 1)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Metabolic Diseases (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 3)

Obesity (Phase 1)

Obesity, Abdominal (Phase 2)

Pharmacokinetics (Phase 1)

Renal Insufficiency (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 18
# of Trial Organizations: 18

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue